PharmaFocus Today – Page 129 – media

Weiming Pharmaceutical plans to sign a sales contract worth 53.978 million yuan

On March 12, Weiming Pharmaceutical announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. plans to sign a “Sales Contract” with Jiangsu Soho Innovation Technology Group Co., Ltd. to purchase the liquid storage system and chromatography system, filler and reaction bags required for the Shandong Weiming Biomedicine Industrial Park project recombinant human nerve growth factor eye drops production workshop from Jiangsu Soho. The total contract price is 53.978 million yuan. The signing of this contract provides hardware guarantee for the industrialization of the company’s existing pipelines, which is conducive to further improving the company’s industrial layout and promoting the continuous growth of the company’s operating performance. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 321
- March 13, 2025
Wholly-owned subsidiary Xiantai Pharmaceutical obtains Spanish AEMPS GMP compliance certificate

On March 12, North China Pharmaceutical announced that its wholly-owned subsidiary North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. received the “Manufacturer GMP Compliance Certificate” issued by the Spanish Medicines and Medical Devices Agency. The production lines involved in the certificate include procaine penicillin series products, benzathine penicillin series products and amoxicillin (sterile), and the inspection conclusion is in compliance with EU GMP principles. Among them, the inspection of amoxicillin (sterile) is the first drug GMP compliance inspection before it is listed in the EU. Xiantai Company is the only domestic amoxicillin (sterile) manufacturer that has passed EUGMP certification. The acquisition of this certificate will have a positive impact on the sales of amoxicillin (sterile) products to the EU market, but will not have a significant impact on the company’s current operating performance. https://finance.eastmoney.com/a/202503133344224416.html
- Source: drugdu
- 306
- March 13, 2025
The “One who swimming against the current” in the generic drug industry

Centralized procurement has led to a sharp drop in the price of generic drugs, which poses a direct challenge to the company’s revenue. However, key generic drug companies such as Beite Pharmaceuticals have maintained steady revenue growth under the background of centralized procurement with their strong R&D strength and market competitiveness. Data show that its sales of pharmaceutical preparations have continued to grow, with a compound growth rate of up to 30.7%, especially in 2021, which has achieved a leapfrog growth. Remarkable performance and steady growth In recent years, Chengdu Beite Pharmaceuticals’ performance has continued to grow, showing strong development resilience and potential. In 2023, the company’s sales of pharmaceutical preparations reached 7.41 billion yuan. From 2016 to 2023, the compound growth rate of sales of preparations was as high as 30.7%, especially in 2021, Beite Pharmaceuticals’ performance achieved a leapfrog growth, a year-on-year increase of 98.0% compared with 2020. ...
- Source: drugdu
- 245
- March 13, 2025
a milestone in the rise of domestic production

In January 2025, the Guizhou Provincial Health Commission launched a centralized procurement project for CT equipment. The total budget of the project is as high as 175.25 million yuan, covering the procurement of 13 sets of CT equipment. Recently, it was announced that the total bid amount for this centralized procurement project was only 78.03 million yuan, which is 44.5% of the budget. Domestic brand CT equipment performed well, and Neusoft Medical became the biggest winner in this bidding, winning 7 sets. 01. Domestic brand wins bid as mainstream The recently announced winning bid for the CT equipment centralized procurement project by the Guizhou Provincial Health Commission shows that the total bid amount for this centralized procurement project is only 78.03 million yuan, which is only 44.5% of the budget and directly saves nearly 100 million yuan in funds. In fierce competition, domestic CT equipment brands have performed well, with ...
- Source: drugdu
- 429
- March 12, 2025
Heavy Ten Year Plan

Recently, Medtronic announced the launch of a “bold” ten-year global plan – Medtronic Spark. 01. Medtronic Spark Program: Lighting the Path to High paying Jobs for Low Income Youth Amidst the global shortage of medical talent, a grand plan aimed at cultivating future leaders in health technology is quietly underway in Galway, Ireland. Global medical technology giant Medtronic has announced the launch of its ten-year “Medtronic Spark” program, aimed at paving a path to high paying health technology careers for one million young people from low-income families. As 2030 approaches, the healthcare and technology industries are facing an unprecedented talent crisis. It is predicted that these two industries will face a total shortage of 15 million professionals, with the health technology sector alone facing a shortage of 4.3 million, and healthcare workers expected to face a huge shortage of 11 million. This severe situation poses a serious challenge to low-income ...
- Source: drugdu
- 325
- March 12, 2025
Sino Biopharmaceuticals and Qingpu Biotechnology Reach Exclusive Cooperation Agreement

Sino Biopharmaceuticals (01177.HK) announced on March 6 that the company recently reached an exclusive cooperation agreement with Nanjing Qingpu Biotechnology Co., Ltd. (hereinafter referred to as “Qingpu Biotechnology”) in mainland China for its developed national Class 2 new drug QP001. According to reports, QP001 is a meloxicam injection registered as a national Class 2 new drug. It is a long-acting, potent new non-steroidal anti-inflammatory drug (NSAIDs) for postoperative pain. Compared with traditional non-selective NSAIDs, QP001 is a selective cyclooxygenase-2 (COX-2) inhibitor that can block the release of COX-2 that causes body pain and inflammation, reduce or block the synthesis of prostaglandins (PGs) in the affected area, thereby playing an anti-inflammatory and analgesic role, while having little effect on cyclooxygenase-1 (COX-1) that maintains normal physiological functions. Therefore, in the future, patients with mild renal impairment, elderly patients and other special groups can also use it normally. China Biopharmaceuticals said that at ...
- Source: drugdu
- 285
- March 12, 2025
Sino Biopharmaceutical’s innovative drug clinical research results are internationally recognized

On March 10, Sino Biopharmaceutical (01177) announced that the Phase Ib/IIa clinical study results of the Group’s independently developed Class 1 innovative drug “Rovadicitinib” for the treatment of chronic graft-versus-host disease (cGVHD) have been published in the top international hematology journal Blood. The drug is the world’s first oral small molecule inhibitor with dual inhibition mechanisms of JAK and ROCK, showing good anti-inflammatory and anti-fibrosis effects. A total of 44 subjects were included in the study, and the results showed that rovadicitinib was well tolerated, with no dose-limiting toxicity. The most common adverse event was anemia, with an incidence of 38.6%. The best overall response rate (BOR) of the study was 86.4%, 72.7% in the glucocorticoid-refractory cohort, and 90.9% in the glucocorticoid-dependent cohort. In addition, 88.6% of the treated subjects reduced their glucocorticoid doses, and 59.1% of the subjects experienced improvement in related symptoms. The Group has submitted a marketing ...
- Source: drugdu
- 299
- March 12, 2025
Yifang Biopharma D-2570 Psoriasis Phase II Clinical Study Results Released

On March 10, Yifang Biopharma (688382) announced that on March 8, 2025, the Phase II clinical study results of the company’s independently developed TYK2 inhibitor D-2570 for the treatment of moderate to severe plaque psoriasis were released in the form of an oral report in the latest breakthrough research abstracts section of the 2025 American Academy of Dermatology Annual Meeting. In terms of safety, D-2570 was generally well tolerated, most adverse events were mild to moderate, and no serious adverse events were reported. Its safety profile is similar to other TYK2 inhibitors, and no new safety signals were found. In addition, data from Phase II clinical studies showed that D-2570 is significantly better than placebo in treating patients with moderate to severe psoriasis, and is also better than similar TYK2 inhibitors currently on the market. It is also comparable in effectiveness to antibody biologics (such as anti-IL-17A and anti-IL-23 antibodies). ...
- Source: drugdu
- 345
- March 12, 2025
When will the HPV vaccine be free? NPC deputies call on the central government to support the vaccination of vulnerable groups

As the most popular self-paid vaccine in the past few years, when the HPV vaccine can become a public product for all has always been the focus of social attention. At the National People’s Congress in recent years, deputies and members have continued to make suggestions on this. Nandu reporters learned that last year, the relevant suggestions were listed as key supervision suggestions by the National Health Commission. This year, deputies and members continued to speak out on this and called for the inclusion of HPV vaccines in the national immunization plan. Because it can prevent cervical cancer, HPV vaccines have been sought after since their birth. The countries that first introduced the vaccination plan have observed a significant decline in HPV infection rates and cervical precancerous lesions. The World Health Organization recommends that 90% of girls should be vaccinated with HPV vaccines before the age of 15 by 2030 ...
- Source: drugdu
- 296
- March 12, 2025
Intelligent regulation of oxygen flow, Weigao takes the lead in launching the first automatic controlled oxygen concentrator

The China Respiratory Science Development Conference pointed out that chronic respiratory problems, represented by chronic obstructive pulmonary disease (COPD), have become the most prominent and severe public health problem in China, with a prevalence rate of 13.7% among people over 40 years old. According to the “Research Report on the Development Trends and Strategies of the Domestic Oxygen Generator Industry from 2023 to 2028” by China Research Institute of Industry, the demand for precision oxygen therapy in the home oxygen therapy market is continuously increasing. Weihai Weigao Health Technology Co., Ltd., a subsidiary of Weigao Group, has taken the lead in launching the first automatic oxygen controlled (AOT) oxygen concentrator to meet the precise oxygen therapy needs of patients, leading the industry development and helping medical progress. 01. Innovative automatic oxygen control technology breaks the limitations of constant oxygen production Traditional oxygen concentrators lack a dynamic adjustment mechanism, making it ...
- Source: drugdu
- 271
- March 11, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.